title: Renal transplantation in patients with familial Mediterranean fever.
abstract: Amyloidosis is the most common and devastating complication of familial Mediterranean fever (FMF). Renal transplantation is the choice of treatment of in most end-stage renal disease (ESRD). We report our experience on the outcomes in eight patients who underwent renal transplantation for ESRD due to FMF secondary to amyloidosis, and we provide a discussion on the current evidence on this topic of study. The clinical charts of eight renal transplant patients (seven male, one female) who underwent ESRD due to FMF-related amyloidosis were investigated. Five patients underwent living-donor renal transplantation and three patients underwent deceased-donor renal transplant. The mean follow-up period was 35 months (range 3-72). All patients were on triple immunosuppressive treatment and received colchicine. All allografts are currently functioning well with a mean serum creatinine level of 1.4 (range 0.7-2.6) mg/dL. Posttransplantation complications included acute rejection (n = 4), chronic rejection (n = 1), severe gastroenteritis (n = 2), and erythrocytosis (n = 5). None of the patients had proteinuria. During follow-up, we did not observe clinically severe FMF attack, septicemia, rhabdomylosis, symptoms related to vasculitis, and clinical neuropathy. The clinical outcome of the patients in this cohort was similar to that of other renal transplant patients with ESRD due to other causes. This study shows favorable prognosis of eight ESRD patients due to amyloidosis caused by FMF after renal transplantation. Renal transplantation is a safe procedure for ESRD patients having amyloidosis due to FMF. Regular use of colchicine after transplantation should be mentioned.
authors.affiliation: Department of Nephrology, Faculty of Medicine, Ondokuz Mayıs University, Samsun 55139, Turkey. emredlk@yahoo.com
authors.forename: Emre
authors.initials: E
authors.lastname: Erdem
authors.forename: Ahmet
authors.initials: A
authors.lastname: Karatas
authors.forename: Coskun
authors.initials: C
authors.lastname: Kaya
authors.forename: Melda
authors.initials: M
authors.lastname: Dilek
authors.forename: Yarkın Kamil
authors.initials: YK
authors.lastname: Yakupoglu
authors.forename: Nurol
authors.initials: N
authors.lastname: Arık
authors.forename: Tekin
authors.initials: T
authors.lastname: Akpolat
mesh_terms: D000328:Adult; D000686:Amyloidosis / Q000188:drug therapy / Q000209:etiology / Q000601:surgery; D015331:Cohort Studies; D003078:Colchicine / Q000008:administration & dosage; D003131:Combined Modality Therapy; D010505:Familial Mediterranean Fever / Q000150:complications*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000188:drug therapy / Q000209:etiology / Q000601:surgery*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011379:Prognosis; D012189:Retrospective Studies; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D003078:Colchicine